–
Apimeds Pharmaceuticals US, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY23 to FY25
millions USD
FY21:
FY22:
–
FY23:
−0.63
FY24:
−0.73
FY25:
−8.93
millions USD
FY21:
–
FY22:
–
FY23:
–
FY24:
–
FY25:
−10.1
Change from FY21 to FY25
millions USD
FY21:
0.40
FY22:
0.28
FY23:
1.03
FY24:
0.33
FY25:
20.6
(positive)
millions USD
FY21:
–
FY22:
–
FY23:
–
FY24:
–
FY25:
−8.98
All amounts in millions USD FY21, FY22: figures supplemented from Twelve Data because the SEC filings do not reach back this far.